The November 20, 2021, article by Wagner et al entitled “nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors” (J Clin Oncol 10.1200/JCO.21.01728) was published with errors.
Under the subsection heading AEs and Dose Reductions, the first sentence of the third paragraph read, “Dose reductions occurred in 34% (13 of 34) of patients; 11 of 13 patients had one dose reduction, and two patients had two dose reductions.” It should have read, “Dose reductions occurred in 38% (13 of 34) of patients; 11 of 13 patients had one dose reduction, and two patients had two dose reductions.”
In Figure 1, panel D, one of the tumors in the TSC1 group was incorrectly characterized as having a missense mutation (reflected by the color olive green) instead of a splice site mutation (reflected by the color purple).
This has been corrected as of October 27, 2023. The authors apologize for the errors.